103561-09-7

Basic information

• Product Name: 3-(4-FORMYL-PHENOXY)-BENZOIC ACID METHYL ESTER
• Synonyms: 3-(4-FORMYL-PHENOXY)-BENZOIC ACID METHYL ESTER;methyl 3-(4-formylphenoxy) benzoate
• CAS NO: 103561-09-7
• Molecular Formula: C₁₅H₁₂O₄
• Molecular Weight: 256.25338
• Mol File: 103561-09-7.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 395.9°C at 760 mmHg
• Flash Point: 176.2°C
• Appearance: /
• Density: 1.222g/cm³
• Vapor Pressure: 1.77E-06mmHg at 25°C
• Refractive Index: 1.595
• CAS DataBase Reference: 3-(4-FORMYL-PHENOXY)-BENZOIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(4-FORMYL-PHENOXY)-BENZOIC ACID METHYL ESTER(103561-09-7)
• EPA Substance Registry System: 3-(4-FORMYL-PHENOXY)-BENZOIC ACID METHYL ESTER(103561-09-7)

Safety Data

• Hazardous Substances Data: 103561-09-7(Hazardous Substances Data)

Usage

General Description

3-(4-Formyl-phenoxy)-benzoic acid methyl ester is an organic compound with the molecular formula C15H12O4. It is a methyl ester derivative of 3-(4-Formyl-phenoxy)-benzoic acid, which is a benzene derivative. This chemical is used as a building block in the synthesis of various pharmaceuticals, agrochemicals, and other organic compounds. It is also used in the production of dyes, pigments, and is widely used in research and development processes. The compound has potential applications in medicinal chemistry and drug discovery due to its unique chemical structure and reactivity.

InChI:InChI=1/C15H12O4/c1-18-15(17)12-3-2-4-14(9-12)19-13-7-5-11(10-16)6-8-13/h2-10H,1H3

Upstream product

• 24856-58-4 1,1-dimethoxy-1-(4-bromophenyl)methane 
• 19438-10-9 methyl 3-hydroxybenzoate 
• 459-57-4 4-fluorobenzaldehyde 

Downstream Products

• 103560-97-0 3-(4-Chlorocarbonyl-phenoxy)-benzoic acid methyl ester 
• 103561-00-8 [4-(3-{2-[4-(3-Hydroxymethyl-phenoxy)-phenyl]-ethyl}-phenoxy)-phenyl]-methanol 
• 103561-01-9 C₂₈H₂₄Cl₂O₂ 
• 103560-99-2 C₃₀H₂₆O₆ 
• 1126633-05-3 4-[3-(pyrrolidine-1-carbonyl)-phenoxy]-benzaldehyde 

Relevant articles and documents

Synthesis and biological evaluation of thielocin B1 analogues as protein-protein interaction inhibitors of PAC3 homodimer

The synthesis and biological evaluation of thielocin B1 analogues have been demonstrated. Fourteen analogues modified in the central core and terminal carboxylic acid moiety were concisely synthesized by simple esterification or etherification reaction. The evaluation of synthetic analogues as inhibitors of proteasome assembling chaperone (PAC) complexes (the PAC3 homodimer and PAC1/PAC2) revealed that the natural product-like bending structure and terminal carboxylic acid groups were crucial for its biological activity. Moreover, SAR and in silico docking studies indicated that all methyl groups on the diphenyl ether moiety of thielocin B1 contribute to the potent and selective inhibition of the PAC3 homodimer via hydrophobic interactions.

THERAPEUTIC INHIBITORY COMPOUNDS

The invention provides compounds of Formula I and Formula II: A-B-C-D-E-F-G-J (I) C-D-E-F-G-J (II) wherein A, B, C, D, E, F, G, and J have any of the values defined in the specification, and salts thereof. The compounds are useful for inhibiting plasma kallikrein, and for treating a disease or condition in an animal where inhibition of plasma kallikrein is indicated.

NOVEL BRADYKININ B1-ANTAGONISTS

The present invention relates to compounds of general formula I wherein n, R1, R2, R3, R4, R5, R6, R7 and R8 are defined as stated hereinafter, the enantiomers, the diastereomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with organic or inorganic acids or bases, which have valuable properties, the preparation thereof, the pharmaceutical compositions containing the pharmacologically effective compounds, the preparation thereof and the use thereof.